Eur Heart J: Risk of heart disease in patients treated with immunosuppressants

A recent study published in Eur Heart J, an authoritative journal in the field of cardiovascular disease, was designed to assess the risk of heart events in patients with lung cancer or malignant melanoma treated with immunosuppressants (ICI).
study included patients with lung cancer or malignant melanoma that occurred continuously throughout Denmark between 2011 and 2017.
the study's main compound outcomes were heart events (arrhythmic arrhythmics, heart or myocarditis, heart failure) or cardiovascular death.
the absolute risk and analyzed the association between ICI and heart events in a multivariate Cox model.
researchers included 25,573 lung cancer patients, 743 of whom were treated with programmed cell death 1 inhibitor (PD1i), with an absolute risk of 9.7% of one-year heart events .95% confidence interval (CI) of 6.8-12.5.
of the 13,568 patients with malignant melanoma, 145 were treated with PD1i, while 212 were treated with cytotoxic T lymphocyte-related protein 4 inhibitors (CTLA-4i).
their one-year risk were 6.6% (1.8-11.3) and 7.5% (3.7-11.3).
risk of heart events was higher than in patients without ICI treatment.
the risk ratio for lung cancer patients was 2.14 (95% CI is 1.50-3.05) and the malignant melanoma patients treated with PD1i and CTLA-4i were 4.30 (1.38-13.42) and 4.93 (2.45-9.99), respectively, within 6 months of the first ICI was given.
6 months, the HRs were 2.26 (1.27-4.02) in lung cancer patients and 3.48 (1.91-6.35) in patients with malignant melanoma treated with CTLA-4i.
, the incidence of heart events in patients with lung cancer and malignant melanoma increased.
。